Trimethoprim-sulfamethoxazole primary prophylaxis in lupus patients taking low-level immunosuppressive treatment Systemic lupus erythematosus Lupus Trimethoprim-sulfamethoxazole Pneumocystis pneumonia
Conditions
Interventions
TMP/SMX was the only agent used for primary prophylaxis in the intervention group of this study. Participants who previously used TMP/SMX must discontinue for at least two weeks before starting TMP/SM
Active Comparator Drug,No Intervention No treatment
TMX/SMX primary prophylaxis,Control
Sponsors
Mahidol university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Lupus patients diagnosed by 2019 EULAR/ACR Criteria for SLE 2.Taking low level immunosuppressive treatment
Exclusion criteria
Exclusion criteria: 1.History of TMP/SMX allergy 2.Need for TMP/SMX treatment 3.Overlap syndrome 4.HIV infection 5.Pregnancy 6. Cancer patient 7.Transplant patient 8.History of TMP/SMX sensitive opportunistic infections within 6 months 9.History of pulse immunosuppressive treatment within 6 months 10.History of CMV infection or CMV disease within 3 months 11.Received pentamidine or dapsone for any indication prior to enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of TMP/SMX sensitive OIs include pneumocystis pneumonia, toxoplasmosis and nocardiosis one year after enrollment Incidence rate by medical record review | — |
Secondary
| Measure | Time frame |
|---|---|
| ADRs of TMP/SMX one year after enrollment Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 | — |
Countries
Thailand
Contacts
Public ContactPaopat Munthananuchat
Faculty of Medicine Ramathibodi Hospital, Mahidol University
Outcome results
None listed